FDMT Q3 2020 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+1274.3% YoY

Gross Profit

-$4M-55.7% margin

Operating Income

-$8M-105.3% margin

Net Income

-$8M-105.6% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+104.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$98M

Total Liabilities

$28M

Stockholders' Equity

$70M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$540,000	+1274.3%
Gross Profit	-$4M	-$9M	+53.2%
Operating Income	-$8M	-$17M	+54.1%
Net Income	-$8M	-$17M	+53.0%